Alternative Promoters Unlock New TNBC Treatment Pathways
Researchers have discovered that alternative promoter usage in triple-negative breast cancer drives tumor heterogeneity and patient outcomes. The HDAC9 gene shows dramatic promoter switching that correlates with survival differences, opening new diagnostic possibilities.